RE: Full allocation5 Mar 2024 21:35
Rorydinho
You have mentioned:
"I’m invested in late clinical stage biotechs which are valued similarly but have much more data, efficacy data, fast-track, ODD, everything that Avacta doesn’t have".
I say:- Good luck to you. HOWEVER, WHAT AVACTA HAS IN TERMS OF ITS CHEMICAL PLATFORM, pre/CISION WHICH, USING EXISTING CHEMOTHERAPY DRUG, SAVE HEALTHY CELLS. NO OTHER BIO COMPANY HAS SUCH PLATFORM, AND, THAT IS THE BIGGEST DIFFERENCE.
UNLIKE AVACTA, MOST BIO COMPANIES, IN SEARCH OF A NEW DRUG, ARE BINARY AND WILL FAIL .